– USA, TX – Apollo Endosurgery, Inc. (NASDAQ: APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Chas McKhann to its Board of Directors as CEO, effective March 1st.
“We are pleased to announce Chas’ appointment, and we want to thank Todd for his excellent stewardship… We are excited to have a proven executive like Chas join Apollo and to lead our management team. The launch of X-Tack represents a potential inflection point in the growth of the company. Chas brings a great depth of experience in successfully commercializing new technologies including securing reimbursement and building strong, supporting medical economics cases.”said Board Chairman John Barr.
About Chas McKhann
Mr. McKhann is a proven MedTech executive with experience at both large device companies such as Boston Scientific and Johnson & Johnson and earlier stage companies such as Torax Medical and Intersect ENT. While at Johnson & Johnson, he played a significant role in the launch of the first drug-eluting stent, Cypher, helping to significantly increase market share. He has extensive hands-on experience in clinical, regulatory, and reimbursement activities supporting a variety of novel and innovative medical devices.
Mr. McKhann started his career at McKinsey & Co. and earned a Bachelor’s degree and Masters of Business Administration from Stanford University.
“This is an exciting time for Apollo,” said Chas McKhann. “As an innovative company with truly game-changing technology, we have the potential to revolutionize gastrointestinal procedures and the management of obesity, improving the lives of millions of patients with GI and bariatric conditions. We have extraordinary opportunities to continue to accelerate the expansion of our product franchises globally. I am honored to lead Apollo and the management team as we execute our strategy of delivering life-changing technology to our patients and generating profitable growth for our Company.”
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on next-generation, minimally invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 75 countries today and include the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, the ORBERA Intragastric Balloon, and the X-Tack Endoscopic HeliX Tacking System.
For more information: https://apolloendo.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
